Trial Profile

Transcriptome and Metabolic Analyses of CHAPLE Disease Patients With or Without Eculizumab Treatment

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eculizumab (Primary)
Indications Immune haemolysis; Inborn genetic disorders; Thrombotic microangiopathy
Focus Pharmacodynamics
Acronyms CHAPLEOMIC

Most Recent Events

04 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified August 2019).
13 Aug 2019 Planned primary completion date changed from 15 Jun 2019 to 15 Sep 2019.
17 May 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com